The authors present an interesting clinical case investigating alpha-glutamyl-tryptophan as an adjunctive intervention following Helicobacter pylori eradication in a patient with chronic atrophic gastritis. The topic is relevant to gastroenterology and clinical pharmacology, particularly because therapeutic strategies aimed at gastric mucosal restoration remain an area of considerable clinical interest. The report has several strengths, including a clearly described treatment regimen, histological and immunohistochemical assessments, endoscopic findings, gastric functional measurements, and a documented follow-up period. The inclusion of written informed consent and the authors' acknowledgment of the limitations inherent in a single-patient observation are also appreciated. Nevertheless, several methodological and interpretative issues limit the scientific significance and generalizability of the findings. 1. Inability to establish a treatment-specific effect The principal limitation is the inability to distinguish the effects of alpha-glutamyl-tryptophan from those of H. pylori eradication. All post-treatment evaluations were performed after both interventions. Consequently, the observed improvements in gastric mucosal inflammation, glandular morphology, and functional parameters cannot be independently attributed to alpha-glutamyl-tryptophan. Although the authors acknowledge this limitation, several statements in the Discussion still imply a treatment-specific regenerative effect. These interpretations should remain explicitly hypothesis-generating. 2. Interpretation of histological improvement The reported increases in gland density and depth, appearance of parietal cells, and reduction in intestinal metaplasia within a relatively short observation period warrant careful interpretation. Gastric intestinal metaplasia may exhibit a heterogeneous distribution, and differences between biopsy samples can influence apparent histological improvement. The reliability of the reported changes would be strengthened by independent pathological assessment, detailed documentation of biopsy-site comparability, and clarification of the quantitative histomorphometric procedures. Importantly, the Kimura–Takemoto classification remained C1 before and after treatment, suggesting that the reported improvement should not be interpreted as complete resolution of gastric atrophy. 3. Interpretation of gastric functional recovery The marked reduction in mean intragastric pH from 6.8 to 1.2, accompanied by substantial changes in pepsinogen I and gastrin-17, represents an important observation. However, these findings require cautious interpretation. Information on medication washout, standardization of pH-monitoring conditions, and the underlying recordings would improve the credibility and reproducibility of these measurements. The observed biochemical and functional changes do not independently establish structural regeneration or identify its underlying pharmacological mechanism. 4. Mechanistic evidence and reference accuracy The discussion attributes the observed effects to modulation of metabotropic glutamate receptors, matrix metalloproteinases, and inflammatory signaling. However, these molecular pathways were not directly investigated in the reported patient. Furthermore, several cited studies concern compounds that differ chemically from alpha-glutamyl-tryptophan. In particular, references 31 and 33 investigate gamma-glutamyl-containing peptides, while reference 34 concerns alpha-glutamyl-lysine and a zinc-containing formulation. These studies should not be presented as direct evidence for the pharmacological activity of the compound used in this case without appropriate qualification. A systematic reassessment of the mechanistic claims and their supporting references is warranted. 5. Assessment of eradication success and clinical follow-up The authors should clarify the timing and conditions of post-treatment H. pylori testing, particularly the interval after antibiotic administration and discontinuation of proton pump inhibitors. These factors are important for interpreting the reliability of eradication confirmation. Additionally, the proposed endoscopic surveillance interval of three years should be individualized according to the patient's histological stage, extent of gastric atrophy, and other risk factors, rather than presented as a universal consequence of the MAPS III recommendations. The three-month follow-up is insufficient to establish sustained regression of intestinal metaplasia, long-term clinical benefit, or any reduction in gastric cancer risk. 6. Limited novelty and incremental contribution The authors have previously contributed to clinical investigations of alpha-glutamyl-tryptophan in chronic atrophic gastritis, including controlled studies evaluating related morphological and functional endpoints. Although the present case provides additional individual-level clinical observations, its incremental scientific contribution beyond the existing literature appears limited. A clearer explanation of the unique clinical insight provided by this case would strengthen its academic value. 7. Statistical interpretation and reporting As a single-patient case report, the study appropriately provides descriptive observations rather than population-level statistical inference. Nevertheless, the reported numerical changes should not be described as demonstrating treatment efficacy, statistical significance, or a validated therapeutic mechanism. Similarly, the absence of adverse events in one patient cannot establish the safety profile of the intervention. Overall assessment This article presents a clinically relevant observation supported by several complementary diagnostic approaches. Its descriptive value is acknowledged, and the authors appropriately recognize some important limitations. However, the absence of a treatment-specific comparator, uncertainty surrounding the interpretation of rapid histological improvement, limited mechanistic validation, concerns regarding the applicability of selected references, and insufficient long-term follow-up substantially restrict the strength of the conclusions. The report should primarily be regarded as an exploratory clinical observation that may help generate hypotheses for future investigations. Controlled clinical studies with standardized biopsy mapping, independent histopathological evaluation, predefined outcome measures, and extended follow-up are required to determine whether alpha-glutamyl-tryptophan provides clinically meaningful benefits beyond H. pylori eradication alone.